The pharmaceutical company, Eisai, recently withdrew Belviq (lorcaserin) from the market at the request of federal regulators. Some members of our patient community began taking Belviq off-label, after reports that it potentially helped with seizure control, even though it received FDA approval as a weight-loss drug.
The abrupt withdrawal of Belviq has caused concerns and challenges for patients with Dravet syndrome who take Belviq off-label. Eisai has established a centralized Expanded Access program, eliminating the need for physicians to submit their own INDs. Neurologists should contact Eisai at email@example.com for assistance obtaining access for their patients.
Read more about off-label use and the market withdrawal of Belviq on this recent Decoding Dravet blog post.